This study confirmed the therapeutical effect of TXYF in reducing intestinal inflammation in liver-depression and spleen-deficiency rats with D-IBS and T2DM, and ameliorating the expression of TNF-α, IL-1β, IL-6, and IL-10 in the colon. Here, IL6 is linked to irritable bowel syndrome.